Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lunesta Has "Encouraging" Debut, Sepracor Says

This article was originally published in The Pink Sheet Daily

Executive Summary

For the week ending April 15, the insomnia agent brought in 21,381 new scripts, resulting in a 5.1% market share, Sepracor said. "It looks like…the principal new Rxs are coming from [Sanofi-Aventis'] Ambien," the company said. Sepracor is planning to pursue labeling adaptations to increase Lunesta's market potential.
Advertisement

Related Content

Ambien CR Gets FDA Approval; Launch Expected In Mid-September
Sepracor Lunesta Cancer Risk At Center Of FDA Approvability Debate
King Lowers Sonata Forecast, Citing Increased Competitive Activity
Sanofi-Aventis Eyes Summer Launch For Ambien CR
Sepracor's "Product And Use" Lunesta Ad To Be "Very Visible," Company Says
Sepracor's "Product And Use" Lunesta Ad To Be "Very Visible," Company Says
Sepracor Insomnia Spot Suggests Lunesta “Product And Use” Ads Coming Soon
Lunesta Schedule IV Placement Effective Immediately, DEA Says
Lunesta Schedule IV Placement Effective Immediately, DEA Says
Sanofi Not "Desperate" To Improve Ambien Label In Face Of Competition

Topics

Advertisement
UsernamePublicRestriction

Register

PS062070

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel